Poseida Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
A Form 4 filing reveals a Poseida Therapeutics director's disposition of shares and options following the company's merger with Roche, including cash and contingent value rights.
Following the merger of Poseida Therapeutics with Roche, a director, Luke Corning, disposed of shares and options as part of the merger agreement.
A Form 4 filing reveals a Poseida Therapeutics director's disposition of shares and options following the company's acquisition by Roche.
A Form 4 filing reveals a Poseida Therapeutics director's disposition of shares and options following the company's merger with Roche.
Following the completion of the merger with Roche, a Poseida Therapeutics director, Cynthia Collins, disposed of her shares and options, receiving cash and contingent value rights.
Following the completion of the merger with Roche, Poseida Therapeutics' CFO, Johanna Mylet, disposed of her shares and options as part of the acquisition agreement.
Poseida Therapeutics' Chief Medical Officer, Syed Ali-aamir Rizvi, disposed of 185,000 common shares and 250,000 stock options as part of the company's merger with Roche.
A Poseida Therapeutics executive, Harry J. Leonhardt, disposed of shares and options following the company's merger with Roche, receiving cash and contingent value rights.
Poseida Therapeutics CEO, Mark J. Gergen, disposed of his shares and options as part of the company's merger with Roche, receiving cash and contingent value rights.
Poseida Therapeutics CEO, Kristin Yarema, disposed of shares and options as part of the company's merger with Roche, receiving cash and contingent value rights.
Executive Chairman Mark J. Gergen of Poseida Therapeutics reports the withholding of shares for tax obligations and acquisition of shares through the employee stock purchase plan.
Poseida Therapeutics' Executive Chairman, Mark J. Gergen, engaged in stock transactions involving the acquisition and sale of 30,000 shares each, as well as the exercise of stock options.
Poseida Therapeutics' Executive Chairman, Mark J. Gergen, exercised stock options and sold shares on November 26, 2024, under a pre-arranged 10b5-1 trading plan.